Press release
2020 Latest Diabetic Retinopathy Market Expected to Grow to $8.6B at a CAGR of 9.1% | Opportunities, Current and Future Players
The study includes analysis of the Diabetic Retinopathy Market, with their company profiles, recent developments, and the key market strategies. Diabetic Retinopathy Market report shows the latest market insights with upcoming trends and breakdowns of products and services. This report provides statistics on the market situation, size, regions and growth factors. Diabetic Retinopathy Market report contains emerging players analyze data including competitive situations, sales, revenue and market share of top manufacturers.Get FREE PDF Sample of the report @ https://www.reportsnreports.com/contacts/requestsample.aspx?name=3639949
Top Company Profile Analysis in this Report
Roche
Novartis
Genentech
Addmedica
Chengdu Kanghong Pharma
Kowa
Wakamoto
CSL Behring
AstraZeneca
Adverum Biotechnologies
and more...
Diabetic retinopathy (DR) is a sight-threatening, prevalent complication of type 1 and 2 diabetes which is characterized by damage to the small blood vessels in the retina. As the most common microvascular complication of diabetes, more than 60% of patients will experience DR within 20 years of developing diabetes. DR the principal cause of preventable vision loss in working-age adults around the world. There are two major clinical stages of diabetic retinopathy: a less severe subtype known as non-proliferative diabetic retinopathy (NPDR), and a vision-threatening subtype known as proliferative diabetic retinopathy (PDR). Signs of mild, moderate, and severe NPDR include microaneurysms, swollen blood vessels, retinal hemorrhages, vascular occlusion, and the accumulation of hard exudates in the choroid layer.
PDR is characterized by the growth of abnormal, new, fragile blood vessels in the retina. These vessels can leak, causing sudden and severe vision loss. Furthermore, abnormal new blood vessels formed in PDR can press on retinal veins, blocking blood flow, causing a condition known as retinal vein occlusion (RVO). Diabetic macular edema (DME) is a potential complication of DR that involves the macula, which is the small, oval-shaped part of the retina that is responsible for high acuity vision. DME is a condition where fluid accumulates within the macular area, causing swelling and retinal thickening. This can lead to sudden vision loss, resulting from the deterioration of the blood-retinal barrier.
Currently, only severe forms of diabetic retinopathy such as PDR and severe NPDR are managed with pharmacotherapy. The standard of care for DME and RVO are anti-angiogenic agents which inhibit vascular endothelial growth factor (VEGF). The most frequently used anti-VEGF drugs are Roche/Genentechs humanized antibodies Lucentis (ranibizumab) and Avastin (bevacizumab), and Bayer/Regenerons fusion protein Eylea (aflibercept). Angiotensin converting enzyme (ACE) inhibitors can be used to treat patients with comorbid hypertension and diabetic retinopathy, while corticosteroids Alimeras Iluvien (fluocinolone acetonide), Allergans Ozurdex (dexamethasone), and MaQaid (triamcinolone acetonide) can be used to treat people with RVO.
There are nine pharmaceutical markets covered in this report and forecast model (US, France, Germany, Italy, Spain, UK, Japan, China, and Australia). GlobalData estimates that drug sales for DR in 2019 were approximately $3.6B across the nine major markets. Over the 10-year forecast period, the market is expected to grow to $8.6B at a CAGR of 9.1%. This growth will be driven by the launch of longer-acting anti-angiogenic products, topical, and oral drug candidates, which are expected to increase patient compliance, addressing some of the key clinical unmet needs for this indication.
Key Highlights of Diabetic Retinopathy Market Report-
- The DR market is expected to grow at a CAGR of 9.1% from 2029 to 2029, reaching a global value of $8.6B.
- GlobalData projects that the marketed for DR, DME, and RVO will experience growth driven by the launch of long-acting anti-angiogenic products, topical, and oral drug candidates.
- Drug developers are also focusing on producing non-steroidal ocular implants and oral DME products that increase patients compliance. These products will reduce the need for patients to attend frequent hospital appointments in order to receive treatment.
- Despite the clear signs of innovation in the DR pipeline, growth will be limited by the loss of market exclusivity for the major brands of anti-VEGFs: Lucentis, Eylea, and Avastin. The emergence of biosimilars will also negatively impact sales by taking critical patient share away from branded products over the forecast window.
- DME is the most sight-threatening complication of DR and this indication is the focus of most drug developers in this therapy area.
- The top selling drug for non-proliferative diabetic retinopathy in 2029 will be Boehringer Ingelheims BI-1467335 because the oral therapy is expected to be well received by patients who will appreciate the convenience of being table to self-administer the drug. Furthermore, BI-1467335 is expected to launch in the US, 5EU, Japan, and Australia by the end of the forecast window.
- The top selling drug for proliferative diabetic retinopathy in 2029 will be Novartis brolucizumab because of its established efficacy profile and lower frequency of administration, compared to Roches Lucentis (ranibizumab) and Bayer/Regenerons Eylea (aflibercept).
- As well as Novartis brolucizumab, other drugs that are specifically in development for retinal vein occlusion are Graybug Visions sunitinib malate CR, Addmedicas hydroxyurea, and Chengdu Kanghongs conbercept.
- Brolucizumab is expected to be the top selling drug in this cohort with conbercept taking the second position with estimated sales of $295.2M in 2029. Both brolucizumab and conbercept are marketed for age-related macular degeneration, have well understood safety and efficacy profiles, and are injected less frequently than Lucentis, Eylea, and Avastin.
- Products focusing on inhibiting neovascularization will generate $6.8B in sales in 2029, followed by anti-neoplastic agents and erythropoietin modulators generating $431.6M and $421.7M in the final year of the forecast window, respectively.
- Some unmet needs such as the need for a more manageable frequency of administration for intravitreal agents will be better addressed in markets such as the US and 5EU, where drugs such as Adverum
- Biotechnologies gene therapy ADVM-022 and Novartis LKA-651 will launch.
- The presence of first-in-class products in the pipeline is evidence of breakthroughs in research allowing more diverse therapeutic targets to be identified and explored in R&D strategies.
Scope of Diabetic Retinopathy Market Report-
- Overview of DR, RVO, and DME including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.
- Annualized DR, RVO, and DME therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in four patient segments (severe non-proliferative diabetic retinopathy, proliferative diabetic retinopathy, diabetic retinopathy and retinal vein occlusion, and diabetic retinopathy and diabetic macular edema) forecast from 2019 to 2029.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the DR, RVO, and DME markets.
- Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for DR, RVO, and DME therapy. The most promising candidates in Phase II and Phase III stages of development are profiled.
- Analysis of the current and future market competition in the global DR, RVO, and DME therapeutics market. Insightful review of the key market drivers, opportunities, and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to Buy this Report-
The report will enable you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global DR therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global DR therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Single User License: US $ 10995
Get FLAT 25% Discount on this Report @ https://www.reportsnreports.com/purchase.aspx?name=3639949
Table of Contents in Diabetic Retinopathy Market Report-
2 Diabetic Retinopathy: Executive Summary
2.1 Consistent Growth Will See the DR Market More than Double in Size from 2019-2029
2.2 Novel Mechanisms of Action and Non-Invasive Routes of Administration Are Being Investigated in Clinical Trials
2.3 Lack of Specific Therapies for Early-Stage DR is a Significant Unmet Need
2.4 Reducing the Burden of Frequent Anti-VEGF Injections Is a Key Priority for Drug Developers
2.5 Sales of Neovascularization Inhibitors Will Exceed $6B in 2029
2.6 What Do Physicians Think?
3 Introduction
3.1 Catalyst
3.2 Related Reports
3.3 Upcoming Related Reports
4 Disease Overview
4.1 Etiology and Pathophysiology
4.2 Classification or Staging Systems
5 Epidemiology
5.1 Disease Background
5.2 Risk Factors and Comorbidities
5.3 Global and Historical Trends
5.4 Forecast Methodology
5.5 Epidemiological Forecast for Diabetic Retinopathy (2019-2029)
5.6 Discussion
6 Disease Management
6.1 Diagnosis Overview
6.2 Treatment Overview
6.3 Pharmacotherapeutic Interventions for DR, RVO, and DME
6.4 Non-Pharmacotherapeutic Treatment Options for Diabetic Retinopathy
6.5 US
6.6 5EU
6.7 Asia-Pacific
7 Competitive Assessment
8 Unmet Needs and Opportunity Assessment
9 Pipeline Assessment
10 Current and Future Players
11 Market Outlook
12 Appendix
and more...
Corporate Headquarters
Tower B5, office 101,
Magarpatta SEZ,
Hadapsar, Pune-411013, India
+ 1 888 391 5441
sales@reportsandreports.com
ReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release 2020 Latest Diabetic Retinopathy Market Expected to Grow to $8.6B at a CAGR of 9.1% | Opportunities, Current and Future Players here
News-ID: 2129249 • Views: …
More Releases from ReportsnReports

DeviceCon Series 2024 - UK Edition | MarketsandMarkets
Future Forward: Redefining Healthcare with Cutting-Edge Devices
Welcome to DeviceCon Series 2024 - Where Innovation Meets Impact!
Join us on March 21-22 at Millennium Gloucester Hotel, 4-18 Harrington Gardens, London SW7 4LH for a groundbreaking convergence of knowledge, ideas, and technology. MarketsandMarkets proudly presents the DeviceCon Series, an extraordinary blend of four conferences that promise to redefine the landscape of innovation in medical and diagnostic devices.
Register Now @ https://events.marketsandmarkets.com/devicecon-series-uk-edition-2024/register
MarketsandMarkets presents…

5th Annual MarketsandMarkets Infectious Disease and Molecular Diagnostics Confer …
London, March 7, 2024 - MarketsandMarkets is thrilled to announce the eagerly awaited 5th Annual Infectious Disease and Molecular Diagnostics Conference, scheduled to take place on March 21st - 22nd, 2024, at the prestigious Millennium Gloucester Hotel, located at 4-18 Harrington Gardens, London SW7 4LH.
This conference promises to be a groundbreaking event, showcasing the latest trends and insights in diagnosis, as well as unveiling cutting-edge technologies that are revolutionizing the…

Infection Control, Sterilization & Decontamination Conference |21st - 22nd March …
MarketsandMarkets is pleased to announce its 8th Annual Infection Control, Sterilisation, and Decontamination in Healthcare Conference, which will take place March 21-22, 2024, in London, UK. With the increased risk of infection due to improper sterilisation and decontamination practices, the safety of patients and healthcare workers is of paramount importance nowadays.
Enquire Now @ https://events.marketsandmarkets.com/infection-control-sterilization-and-decontamination-conference/
This conference aims to bring together all the stakeholders to discuss the obstacles in achieving…

Breast Augmentation Market Key Players, Demands, Cost, Size, Procedure, Shape, S …
The global Breast Augmentation Market in terms of revenue was estimated to be worth $900 million in 2020 and is poised to reach $1,692 million by 2025, growing at a CAGR of 13.4% from 2020 to 2025. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying…
More Releases for DME
Dimethyl Ether (DME) & R-DME Market Expansion and Future Trends | 2025 To 2034 O …
The Global Dimethyl Ether (DME) & R-DME Market Size, Scope, and Forecast 2025-2034 report is now part of Exactitude Consultancy's Market Research collection. Industry experts and researchers provide an authoritative and concise analysis of the Dimethyl Ether (DME) & R-DME Market, covering key aspects such as growth drivers, challenges, restraints, developments, and opportunities. This report delivers a precise evaluation of shifting market dynamics and emerging trends. Additionally, it offers a…
DME Service Solutions Partners with the AAHomecare
DME Service Solutions, a leader in providing B2B outsourcing solutions specializing in healthcare, is thrilled to announce its partnership with the American Association for Homecare (AAHomecare). This partnership allows DME Service Solutions to engage with a community dedicated to advancing quality care and operational efficiency in the homecare industry.
AAHomecare has served the home medical equipment (HME) industry for nearly four decades, advocating for improved access to quality homecare products…
Global Airport Ground DME Market Analysis (2020-2025)
Global Info Research offers a latest published report on Airport Ground DME Analysis and Forecast 2020-2025 delivering key insights and providing a competitive advantage to clients through a detailed report. This report focuses on the key global Airport Ground DME Concentrate players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in next few years.
Click to view the full report TOC, figure…
Global Durable Medical Equipment (DME) Market Insights, Forecast
Durable Medical Equipment (DME) is a medical equipment that durable, can be used in the home and have at least 3 years of life expectancy. The prevalence of chronic conditions, such as heart disorders, cancer, gynecological disorders, and neurological disorder is on a rise, demand of long term care and hospitalization for treatment of these disorders is anticipated to facilitate the demand for durable medical equipment. The global Durable Medical…
Durable Medical Equipment (DME) Global Market 2019
Press Release – 30 Jan 2019
Research and Development News --
. .
Latest Update "Global Durable Medical Equipment (DME) Market By Type, By Therapeutic and monitoring Devices Type, By End User, By Region, By Country (2018 Edition) - Forecast to 2023-By Type (Personal Mobility devices, Therapeutic and Monitoring Devices, Medical Furniture, Others), By Sub-Type (Oxygen Equipment, Blood Sugar Monitors, Continuous Passive Motions, Nebulizers, Other Devices), By End User (Hospitals and Clinics,…
Dimethyl Ether (DME) Market - Asia Pacific is a major market for DME | Mitsubish …
Majority of the DME manufactured these days is an end-product of two-step process where the first step involves methanol generation with the help of natural gas or coal being used a feedstock. And the second step involves dehydration of methanol for the production of DME. Dimethyl Ether has the potential of replacing diesel in the conventional engines with small modifications that need to be made in the fuel injecting systems.…